Hos personerne med let nedsat leverfunktion sås en let forhøjet plasma- Cmax for amprenavir (17%), en let forhøjet plasma- AUC( 0- 12) for amprenavir (22%), tilsvarende totale plasma- C12 - værdier for amprenavir og cirka 117% højere plasma- C12- værdier for ubundet amprenavir.
In subjects with mild hepatic impairment (Child-Pugh score of 5-6), the dosage regimen of fosamprenavir 700 mg twice daily with a reduced dosing frequency of ritonavir 100 mg once daily provided slightly higher plasma amprenavir Cmax (17%), slightly higher plasma amprenavir AUC(0-12) (22%), similar plasma total amprenavir C12 values and approximately 117% higher plasma unbound amprenavir C12 values compared to subjects with normal hepatic function receiving the standard fosamprenavir / ritonavir 700 mg / 100 mg twice daily regimen.